RCA
VRTX icon

Resonant Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Resonant Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$793K Buy
1,776
+210
+13% +$97.9K 0.04% 201
2025
Q4 		$710K Buy
1,566
+102
+7% +$44K 0.04% 201
2025
Q3 		$573K Sell
1,464
-94
-6% -$39.3K 0.03% 229
2025
Q2 		$694K Buy
1,558
+108
+7% +$49.8K 0.04% 199
2025
Q1 		$703K Buy
1,450
+183
+14% +$85.3K 0.05% 174
2024
Q4 		$510K Buy
1,267
+41
+3% +$19K 0.04% 204
2024
Q3 		$570K Buy
1,226
+145
+13% +$69.7K 0.04% 202
2024
Q2 		$507K Buy
1,081
+276
+34% +$120K 0.04% 203
2024
Q1 		$336K Buy
+805
New +$340K 0.03% 250

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Resonant Capital Advisors's VRTX Position: Q1 2026 in Review

Resonant Capital Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q1 2026, buying an estimated $97.9K and bringing the position to 1,776 shares worth $793K. The position accounts for 0.04% of the portfolio, ranked #201.

Resonant Capital Advisors first reported a position in VRTX in Q1 2024 and has held it in 9 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Resonant Capital Advisors held 1,776 shares of Vertex Pharmaceuticals worth $793K as of Q1 2026.
  • Resonant Capital Advisors bought 210 Vertex Pharmaceuticals shares in Q1 2026, an estimated $97.9K.
  • Vertex Pharmaceuticals made up 0.04% of Resonant Capital Advisors's portfolio in Q1 2026, its #201 holding.
  • Resonant Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Resonant Capital Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.